You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,695,308


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,695,308 protect, and when does it expire?

Patent 10,695,308 protects REMODULIN and is included in one NDA.

This patent has thirteen patent family members in nine countries.

Summary for Patent: 10,695,308
Title:Inhalation formulations of treprostinil
Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
Inventor(s): Wade; Michael (Chapel Hill, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:16/131,248
Patent Claim Types:
see list of patent claims
Use; Formulation;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,695,308: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for inventors, researchers, and businesses to navigate the complex landscape of intellectual property. This article delves into the details of United States Patent 10,695,308, titled "Inhalation formulations of treprostinil," to provide a thorough analysis of its scope, claims, and the broader patent landscape.

Overview of the Patent

Patent Number and Title

The patent in question is US10695308B2, titled "Inhalation formulations of treprostinil." This patent describes novel methods and formulations for the treatment of various diseases using treprostinil or its derivatives[4].

Assignee and Priority Date

The patent is assigned to United Therapeutics Corp., with a priority date of December 16, 2016. This indicates that the initial application was filed on this date, and any subsequent filings or continuations would build upon this priority date[4].

Scope of the Patent

Invention Description

The patent focuses on inhalation formulations of treprostinil, a prostacyclin analogue used in the treatment of pulmonary arterial hypertension (PAH) and other related conditions. The invention includes methods for preparing these formulations, which are designed to improve the efficacy and safety of treprostinil administration via inhalation[4].

Key Components

  • Treprostinil and Derivatives: The patent covers the use of treprostinil and its pharmaceutically acceptable salts or derivatives.
  • Inhalation Formulations: The formulations are designed for inhalation, which is a novel delivery method for this drug.
  • Therapeutic Applications: The patent includes treatments for diseases such as PAH, secondary pulmonary hypertension, and other vascular diseases[4].

Claims Analysis

Independent and Dependent Claims

The patent includes a set of independent and dependent claims that define the scope of the invention.

  • Independent Claims: These claims stand alone and define the broadest scope of the invention. For example, Claim 1 might describe the inhalation formulation of treprostinil in general terms.
  • Dependent Claims: These claims build upon the independent claims and provide more specific details. For instance, a dependent claim might specify the concentration of treprostinil in the formulation or the method of preparing it[4].

Claim Coverage Matrix

To understand the full scope of the patent, a Claim Coverage Matrix can be useful. This matrix categorizes the claims by scope concepts, helping to identify which patents and claims are actively protecting the intellectual property and where gaps or opportunities exist. This approach is particularly useful for managing large numbers of patent claims[3].

Patent Landscape

Global Patent Family

The patent is part of a global patent family, which includes related applications filed in other countries. Using tools like the Global Dossier provided by the USPTO, one can access the file histories of related applications from participating IP Offices, including the IP5 Offices (USPTO, EPO, JPO, KIPO, and CNIPA)[1].

Prior Art and Citations

The patent cites prior art related to treprostinil and its use in treating various diseases. The Common Citation Document (CCD) application can be used to consolidate prior art cited by all participating offices for the family members of this patent application, providing a comprehensive view of the prior art landscape[1].

Competitor Analysis

Analyzing the patent landscape also involves looking at competitors who may be working on similar technologies. Tools like Patent Analytics can help track patents by claims and scope concepts, identifying gaps or opportunities in the market. This can include categorizing patents by overarching scope concepts to filter, search, and analyze large numbers of patent claims concurrently[3].

International Search and Databases

Searching International Patent Offices

To ensure that the idea has not been patented abroad, it is essential to search international patent databases. Resources such as the European Patent Office's esp@cenet, the Japan Patent Office's database, and the World Intellectual Property Organization's PATENTSCOPE ® Search Service provide access to international patent applications and machine translations for some documents[1].

Practical Applications and Future Directions

Clinical Implications

The inhalation formulations of treprostinil described in the patent have significant clinical implications. They offer a potentially more convenient and effective delivery method for patients with PAH and other related conditions, improving patient compliance and outcomes.

Future Research and Development

The patent highlights future design opportunities and potential areas for further research. For example, the development of new formulations or delivery methods could expand the therapeutic applications of treprostinil. Using tools like Claim Charts, engineers, scientists, and management can review patent coverage and identify areas for innovation[3].

Key Takeaways

  • Understanding the Scope: The patent covers inhalation formulations of treprostinil, including methods for preparation and therapeutic applications.
  • Claims Analysis: Independent and dependent claims define the scope of the invention, with tools like Claim Coverage Matrix aiding in managing and analyzing these claims.
  • Global Patent Landscape: The patent is part of a global family, with tools like Global Dossier and CCD providing insights into related applications and prior art.
  • Competitor Analysis: Patent Analytics helps in tracking competitors and identifying market gaps and opportunities.
  • International Search: Searching international databases ensures that the idea is not patented abroad.

FAQs

Q: What is the primary focus of United States Patent 10,695,308?

A: The primary focus is on inhalation formulations of treprostinil for the treatment of diseases such as pulmonary arterial hypertension.

Q: How can one analyze the claims of this patent effectively?

A: Using a Claim Coverage Matrix and tools like Claim Charts can help in categorizing and analyzing the claims to identify gaps and opportunities.

Q: What resources are available for searching international patent databases?

A: Resources include the European Patent Office's esp@cenet, the Japan Patent Office's database, and the World Intellectual Property Organization's PATENTSCOPE ® Search Service.

Q: What are the clinical implications of the inhalation formulations described in the patent?

A: The formulations offer a potentially more convenient and effective delivery method for patients with PAH and other related conditions, improving patient compliance and outcomes.

Q: How can businesses use patent analytics to their advantage?

A: Businesses can use patent analytics to track patents by claims and scope concepts, identify market gaps and opportunities, and determine the value of their patent claims.

Sources

  1. USPTO - Search for patents. Retrieved from https://www.uspto.gov/patents/search
  2. U.S. Patent and Trademark Office (USPTO) | USAGov. Retrieved from https://www.usa.gov/agencies/u-s-patent-and-trademark-office
  3. Patent Analytics | Intellectual Property Law. Retrieved from https://www.slwip.com/services/patent-analytics/
  4. US10695308B2 - Inhalation formulations of treprostinil. Retrieved from https://patents.google.com/patent/US10695308B2/en

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,695,308

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
United Therap REMODULIN treprostinil INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021272-001 May 21, 2002 AP RX Yes Yes ⤷  Subscribe ⤷  Subscribe A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION ⤷  Subscribe
United Therap REMODULIN treprostinil INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021272-002 May 21, 2002 AP RX Yes Yes ⤷  Subscribe ⤷  Subscribe A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION ⤷  Subscribe
United Therap REMODULIN treprostinil INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021272-003 May 21, 2002 AP RX Yes Yes ⤷  Subscribe ⤷  Subscribe A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION ⤷  Subscribe
United Therap REMODULIN treprostinil INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021272-004 May 21, 2002 AP RX Yes Yes ⤷  Subscribe ⤷  Subscribe A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION ⤷  Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-005 Jul 30, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.